In 2009, the American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS) published standards for the safe use of parenteral chemotherapy in the outpatient setting, including issues of practitioner orders, preparation, and administration of medication. In 2011, these were updated to include inpatient facilities. In December 2011, a multistakeholder workgroup met to address the issues associated with orally administered antineoplastics, under the leadership of ASCO and ONS. The workgroup participants developed recommended standards, which were presented for public comment. Public comments informed final edits, and the final standards were reviewed and approved by the ASCO and ONS Boards of Directors. Significant newly identified recommendations include those associated with drug prescription and the necessity of ascertaining that prescriptions are filled. In addition, the importance of patient and family education regarding administration schedules, exception procedures, disposal of unused oral medication, and aspects of continuity of care across settings were identified. This article presents the newly developed standards.
References
Jacobson JO, Polovich M, McNiff KK, et al: American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 27: 5469-5475, 2009
Jacobson JO, Polovich M, Gilmore TR, et al: Revisions to the 2009 American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards: Expanding the scope to include inpatient settings. J Oncol Pract 8: 2-6, 2012
Halfdanarson TR, Jatoi A: Oral cancer chemotherapy: The critical interplay between patient education and patient safety. Curr Oncol Rep 12:247-252, 2010
Irshad S, Maisey N: Considerations when choosing oral chemotherapy: Identifying and responding to patient need. Eur J Canc Care 19:5-511, 2010
Weingart SN, Toro J, Spencer J, et al: Medication errors involving oral chemotherapy. Cancer 116:2455-52464, 2010
Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56-66, 2009
Hartigan K: Patient education: The cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 7:21-524, 2003
Weingart S, Brown E, Bach PB, et al: NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 6: S1-S14, 2008 (suppl 3)
Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-5115, 1997
Wong SF, Nguyen CP, et al: Outcome assessment of an oral chemotherapy management clinic: A preliminary report. J Clin Oncol 30, 2012 (suppl 34; abstr 105)
McNiff KK, Bonelli KR, Jacobson JO: Quality Oncology Practice Initiative certification program: Overview, measure scoring methodology, and site assessment standards. J Oncol Pract 5:270-276, 2009
Bedell C: A changing paradigm for cancer treatment: The advent of new oral chemotherapy agents. Clin J Oncol Nurs 7:5-9, 2003
Markert A, Thierry V, Kieber M, et al: Chemotherapy safety and severe adverse events in cancer patients: Strategies to efficiently avoid chemotherapy errors in inand outpatient treatment. Intl J Canc 124:722-728, 2009
Lilleyman JS, Lennard L: Non-compliance with oral chemotherapy in childhood leukaemia. BMJ 313:1219, 1996
Landier W: Adherence to oral chemotherapy in childhood acute lymphoblastic leukemia: An evolutionary concept analysis. Oncol Nurs Forum 38:343-352, 2011
Hede K: Increase in oral cancer drugs raises thorny issues for oncology practices. J Natl Cancer Inst 101:1534-1526, 2009
Neugut A, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29: 2534-2542, 2011